Mary Louise Affronti
Associate Professor in the School of Nursing
Dr. Mary Lou Affronti joined the Duke University School of Nursing faculty in February 2014. She earned both her DNP and her MSN at DUSON, and also earned a Master’s degree in Health Science in Clinical Research from the Duke University School of Medicine. She holds a Clinical Associate faculty appointment in the Duke University Medical Center Department of Surgery /Neurosurgery. She is also Senior Investigator and Adult Nurse Practitioner at the Preston Robert Tisch Brain Tumor Center in the Duke Cancer Institute.
Dr. Affronti has been a part of Duke’s oncology clinical and research community for almost three decades, and has been associated with DUSON since 1989 in a variety of roles, including clinical associate, guest lecturer, preceptor, and clinical instructor. She was instrumental in developing the oncology curriculum for DUSON nurse practitioner students. In 2005, she was honored by the Friends of Nursing at Duke with the Evelyn Morgan Award for Excellence in Oncology Nursing. Dr. Affronti’s DNP capstone on adherence to antiemetic guidelines in patients with malignant glioma, which received the Outstanding Capstone Doctoral Project Award in 2013, has just been published in Supportive Care in Cancer.
Dr. Affronti has been developing and leading therapeutic and supportive care research while continuing to see patients as a nurse practitioner, and is continuing both her clinical and research activities at the Brain Tumor Center. She has a strong interest in the development and testing of therapies for primary brain tumors, and is currently a co-principal or principal investigator on four Phase II clinical trials at the Brain Tumor Center.
Current Appointments & Affiliations
Education, Training, & Certifications
Some information on this profile has been compiled automatically from
Duke databases and external sources. (Our
About page explains how this works.)
If you see a problem with the information, please write to
Scholars@Duke and let us know. We will